← Leaderboards
Kai W Wucherpfennig
Dana-Farber Cancer Inst
$37,935,181
Attributed
$44,283,922
Total exposure
30
Grants
26
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.9M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$67,094,635 · 31
By mechanism
P01$35,975,756 · 13
R01$24,347,019 · 10
DP3$3,876,825 · 1
T32$2,382,757 · 1
R56$433,385 · 1
P30$57,573 · 1
Top collaborators
- John Christopher Love13 shared
- Vijay K Kuchroo12 shared
- Shannon J Turley12 shared
- Stephen Gottschalk5 shared
- Xiaole Shirley Liu1 shared
- Hao Wu1 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Shannon J Turley$5,420,711
Others in their field
Top investigators on “T-Lymphocyte”
- Barton F Haynes · Duke University$296,833,570
- Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
- Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
- Alessandro Sette · La Jolla Institute For Immunology$75,756,097
- Rama Rao Amara · Emory University$69,530,112
Research focus
T-LymphocyteBaseCellsProgramsMouse ModelProteinsPathway InteractionsAntigen PresentationComplexStructureMolecularAutoimmune DiseasesAffinityAntibodiesFundingGene ExpressionMultiple SclerosisSignal TransductionMalignant NeoplasmsPeptidesImmunotherapyLigandsAutoimmunityTumor
Grant awards (134)
The Epigenetic Enzyme CARM1 as a Negative Regulator of Dendritic cells and CD8 T cells in Melanoma$683,670
P01 · FY2025 · CA · contact PI
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway$652,196
R01 · FY2025 · CA · contact PI
Program 11 Cancer Immunology$30,085
P30 · FY2025 · CA · contact PI
The Epigenetic Enzyme CARM1 as a Negative Regulator of Dendritic cells and CD8 T cells in Melanoma$700,514
P01 · FY2024 · CA · contact PI
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer$461,120
R01 · FY2024 · CA · contact PI
Proj. 3: Immunosuppressive circuits in T cells and other immune cells in GBM patients enrolled in clinical trials$341,221
P01 · FY2024 · CA · contact PI
Core 1: Tumor Processing and Single Cell RNA sequencing Core$339,055
P01 · FY2024 · CA · contact PI
Program 11 Cancer Immunology$27,488
P30 · FY2024 · CA · contact PI
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway$510,440
R01 · FY2023 · CA · contact PI
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer$475,682
R01 · FY2023 · CA · contact PI
Transcriptional and epigenetic mechanisms of immunotherapy resistance in melanoma$360,208
P01 · FY2023 · CA · contact PI
Proj. 3: Immunosuppressive circuits in T cells and other immune cells in GBM patients enrolled in clinical trials$351,997
P01 · FY2023 · CA · contact PI
Core 1: Tumor Processing and Single Cell RNA sequencing Core$349,761
P01 · FY2023 · CA · contact PI
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway$510,440
R01 · FY2022 · CA · contact PI
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer$475,682
R01 · FY2022 · CA · contact PI
Transcriptional and epigenetic mechanisms of immunotherapy resistance in melanoma$360,208
P01 · FY2022 · CA · contact PI
Proj. 3: Immunosuppressive circuits in T cells and other immune cells in GBM patients enrolled in clinical trials$351,997
P01 · FY2022 · CA · contact PI
Core 1: Tumor Processing and Single Cell RNA sequencing Core$349,761
P01 · FY2022 · CA · contact PI
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway$188,822
R01 · FY2022 · CA · contact PI
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway$520,857
R01 · FY2021 · CA · contact PI
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer$485,407
R01 · FY2021 · CA · contact PI
Transcriptional and epigenetic mechanisms of immunotherapy resistance in melanoma$367,559
P01 · FY2021 · CA · contact PI
Proj. 3: Immunosuppressive circuits in T cells and other immune cells in GBM patients enrolled in clinical trials$359,181
P01 · FY2021 · CA · contact PI
Core 1: Tumor Processing and Single Cell RNA sequencing Core$356,899
P01 · FY2021 · CA · contact PI
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway$125,695
R01 · FY2021 · CA · contact PI
Regulators of Cancer Immunotherapy Response$591,752
R01 · FY2020 · CA · contact PI
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway$520,857
R01 · FY2020 · CA · contact PI
Cancer Immunology Training Grant$505,667
T32 · FY2020 · CA · contact PI
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer$485,407
R01 · FY2020 · CA · contact PI
Proj. 3: Immunosuppressive circuits in T cells and other immune cells in GBM patients enrolled in clinical trials$398,683
P01 · FY2020 · CA · contact PI
Core 1: Tumor Processing and Single Cell RNA sequencing Core$396,400
P01 · FY2020 · CA · contact PI
Transcriptional and epigenetic mechanisms of immunotherapy resistance in melanoma$367,559
P01 · FY2020 · CA · contact PI
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway$520,857
R01 · FY2019 · CA · contact PI
Regulators of Cancer Immunotherapy Response$497,881
R01 · FY2019 · CA
Cancer Immunology Training Grant$469,385
T32 · FY2019 · CA · contact PI
Transcriptional and epigenetic mechanisms of immunotherapy resistance in melanoma$384,559
P01 · FY2019 · CA · contact PI
Cancer Immunology Training Grant$472,152
T32 · FY2018 · CA · contact PI
Antigen Presentation and T cell Programming in Human Autoimmune Diseases$1,659,082
P01 · FY2017 · AI · contact PI
Cancer Immunology Training Grant$472,299
T32 · FY2017 · CA · contact PI
Molecular Characterization of Myelin-Specific T cells from MS Patients$392,781
P01 · FY2017 · AI · contact PI
Scientific Leadership and Administrative Coordination of PPG$44,208
P01 · FY2017 · AI · contact PI
Cancer Immunology Training Grant$10,238
T32 · FY2017 · CA · contact PI
Antigen Presentation and T cell Programming in Human Autoimmune Diseases$1,669,628
P01 · FY2016 · AI · contact PI
Reprogramming of T cells for the Treatment of Melanoma$995,664
R01 · FY2016 · CA · contact PI
Cancer Immunology Training Grant$453,016
T32 · FY2016 · CA · contact PI
Molecular Characterization of Myelin-Specific T cells from MS Patients$293,291
P01 · FY2016 · AI · contact PI
Scientific Leadership and Administrative Coordination of PPG$28,473
P01 · FY2016 · AI · contact PI
Antigen Presentation and T cell Programming in Human Autoimmune Diseases$1,678,728
P01 · FY2015 · AI · contact PI
Reprogramming of T cells for the Treatment of Melanoma$995,664
R01 · FY2015 · CA · contact PI
Molecular Characterization of Myelin-Specific T cells from MS Patients$436,155
P01 · FY2015 · AI · contact PI
Scientific Leadership and Administrative Coordination of PPG$37,671
P01 · FY2015 · AI · contact PI
Antigen Presentation and T cell Programming in Human Autoimmune Diseases$1,687,624
P01 · FY2014 · AI · contact PI
Reprogramming of T cells for the Treatment of Melanoma$995,664
R01 · FY2014 · CA · contact PI
Molecular mechanisms of HLA-DM mediated peptide exchange$433,385
R56 · FY2014 · AI · contact PI
Molecular Characterization of Myelin-Specific T cells from MS Patients$332,847
P01 · FY2014 · AI · contact PI
Scientific Leadership and Administrative Coordination of PPG$31,059
P01 · FY2014 · AI · contact PI
Antigen Presentation and T cell Programming in Human Autoimmune Diseases$1,791,565
P01 · FY2013 · AI · contact PI
Reprogramming of T cells for the Treatment of Melanoma$965,794
R01 · FY2013 · CA · contact PI
Structural Determinants of TCR Assembly and Signaling$402,053
R01 · FY2013 · AI · contact PI
Molecular Characterization of Myelin-Specific T cells from MS Patients$316,356
P01 · FY2013 · AI · contact PI
Scientific Leadership and Administrative Coordination of PPG$35,286
P01 · FY2013 · AI · contact PI
Impact of MHC Genotype on Ex Vivo T cell Function in Type 1 Diabetes$3,876,825
DP3 · FY2012 · DK · contact PI
Antigen Presentation in Human Autoimmune Diseases$1,768,700
P01 · FY2012 · AI · contact PI
Reprogramming of T cells for the Treatment of Melanoma$1,014,415
R01 · FY2012 · CA · contact PI
Structural Determinants of TCR Assembly and Signaling$427,715
R01 · FY2012 · AI · contact PI
Antigen Presentation to Self-reactive T Cells in Human Autoimmune Diseases$359,464
P01 · FY2012 · AI · contact PI
Inhibition of Antigen Presentation in Multiple Sclerosis$347,382
R01 · FY2012 · NS · contact PI
Novel Tools for Immune Monitoring in Autoimmune Diseases$94,074
P01 · FY2012 · AI · contact PI
Administrative Core$26,055
P01 · FY2012 · AI · contact PI
Antigen Presentation in Human Autoimmune Diseases$1,684,111
P01 · FY2011 · AI · contact PI
Structural Determinants of TCR Assembly and Signaling$427,715
R01 · FY2011 · AI · contact PI
Inhibition of Antigen Presentation in Multiple Sclerosis$347,382
R01 · FY2011 · NS · contact PI
Antigen Presentation to Self-reactive T Cells in Human Autoimmune Diseases$332,727
P01 · FY2011 · AI · contact PI
Novel Tools for Immune Monitoring in Autoimmune Diseases$128,480
P01 · FY2011 · AI · contact PI
Administrative Core$72,911
P01 · FY2011 · AI · contact PI
MECHANISM OF PEPTIDE LOADING ONTO HUMAN MHC CLASS II MOLECULES$5,487
P41 · FY2011 · RR · contact PI
Antigen Presentation in Human Autoimmune Diseases$1,730,806
P01 · FY2010 · AI · contact PI
Antigen Presentation to Self-reactive T Cells in Human Autoimmune Diseases$982,670
P01 · FY2010 · AI · contact PI
Structural Determinants of TCR Assembly and Signaling$429,000
R01 · FY2010 · AI · contact PI
Inhibition of Antigen Presentation in Multiple Sclerosis$350,927
R01 · FY2010 · NS · contact PI
Novel Tools for Immune Monitoring in Autoimmune Diseases$70,490
P01 · FY2010 · AI · contact PI
Administrative Core$39,692
P01 · FY2010 · AI · contact PI
Antigen Presentation in Human Autoimmune Diseases$1,698,517
P01 · FY2009 · AI · contact PI
Antigen Presentation to Self-reactive T Cells in Human Autoimmune Diseases$942,068
P01 · FY2009 · AI · contact PI
Structural Determinants of TCR Assembly and Signaling$428,674
R01 · FY2009 · AI · contact PI
TCR Crossreactivity in autoimmune Diseases$391,041
R01 · FY2009 · AI · contact PI
Inhibition of Antigen Presentation in Multiple Sclerosis$354,471
R01 · FY2009 · NS · contact PI
Novel Tools for Immune Monitoring in Autoimmune Diseases$71,255
P01 · FY2009 · AI · contact PI
Antigen Presentation in Human Autoimmune Diseases$64,414
P01 · FY2009 · AI · contact PI
Administrative Core$40,160
P01 · FY2009 · AI · contact PI
Antigen Presentation in Human Autoimmune Diseases$1,649,041
P01 · FY2008 · AI · contact PI
Antigen Presentation to Self-reactive T Cells in Human Autoimmune Diseases$914,628
P01 · FY2008 · AI · contact PI
Inhibition of Antigen Presentation in Multiple Sclerosis$393,058
R01 · FY2008 · NS · contact PI
TCR Crossreactivity in autoimmune Diseases$391,041
R01 · FY2008 · AI · contact PI
Mechanisms of Antigen Presentation by MHC class II$357,882
R01 · FY2008 · AI · contact PI
Novel Tools for Immune Monitoring in Autoimmune Diseases$69,179
P01 · FY2008 · AI · contact PI
Administrative Core$38,989
P01 · FY2008 · AI · contact PI
COMPLEX OF TCR/HLA-DR2/MBP-PEPTIDE$6,417
P41 · FY2008 · RR · contact PI
Antigen Presentation in Human Autoimmune Diseases$820,009
P01 · FY2007 · AI · contact PI
TCR Crossreactivity in autoimmune Diseases$398,615
R01 · FY2007 · AI · contact PI
Structural Determinants of TCR Assembly and Signaling$364,813
R01 · FY2007 · AI · contact PI
Mechanisms of Antigen Presentation by MHC class II$364,813
R01 · FY2007 · AI · contact PI
COMPLEX OF TCR/HLA-DR2/MBP-PEPTIDE$5,059
P41 · FY2007 · RR · contact PI
Antigen Presentation in Human Autoimmune Diseases$820,861
P01 · FY2006 · AI · contact PI
TCR Crossreactivity in autoimmune Diseases$409,349
R01 · FY2006 · AI · contact PI
Mechanisms of Antigen Presentation by MHC class II$375,709
R01 · FY2006 · AI · contact PI
Structural Determinants of TCR Assembly and Signaling$375,709
R01 · FY2006 · AI · contact PI
Inhibition of Antigen Presentation in Multiple Sclerosis$344,579
R01 · FY2006 · NS · contact PI
Antigen Presentation in Human Autoimmune Diseases$817,118
P01 · FY2005 · AI
Mechanisms of Antigen Presentation by MHC class II$384,750
R01 · FY2005 · AI
Structural Determinants of TCR Assembly and Signaling$384,750
R01 · FY2005 · AI
TCR Crossreactivity in Autoimmune Diseases$355,300
R01 · FY2005 · AI
Inhibition of Antigen Presentation in Multiple Sclerosis$353,241
R01 · FY2005 · NS
THE COMPLEX OF TCR/HLA-DR2/MBP-PEPTIDE$4,357
P41 · FY2005 · RR
Antigen Presentation in Human Autoimmune Diseases$791,536
P01 · FY2004 · AI
Mechanisms of Antigen Presentation by MHC class II$384,750
R01 · FY2004 · AI
Structural Determinants of TCR Assembly and Signaling$384,750
R01 · FY2004 · AI
Inhibition of Antigen Presentation in Multiple Sclerosis$353,597
R01 · FY2004 · NS
Structural Determinants of TCR Assembly and Signaling$384,750
R01 · FY2003 · AI
Antigen Presentation in Human Autoimmune Diseases$384,738
P01 · FY2003 · AI
Inhibition of Antigen Presentation in Multiple Sclerosis$353,944
R01 · FY2003 · NS
ANTIGEN PRESENTATION IN HUMAN AUTOIMMUNE DISEASES$689,881
P01 · FY2002 · AI
SPECIFICITY AND DEGENERACY OF AUTOREACTIVE T CELL RECEPT$320,475
R01 · FY2002 · NS
ANTIGEN PRESENTATION IN HUMAN AUTOIMMUNE DISEASES$75,000
P01 · FY2002 · AI
TCR recognition of MHC class II peptide compexes in multiple sclerosis$0
P01 · FY2002 · AI
TCR recognition of MHC class II peptide compexes in multiple sclerosis$0
P01 · FY2002 · AI
ANTIGEN PRESENTATION IN HUMAN AUTOIMMUNE DISEASES$673,375
P01 · FY2001 · AI
SPECIFICITY AND DEGENERACY OF AUTOREACTIVE T CELL RECEPT$311,143
R01 · FY2001 · NS
MOLECULAR MECHANISMS OF MHC LINKED SUSCEPTIBILITY$203,598
R01 · FY2001 · AI
TCR recognition of MHC class II peptide compexes in multiple sclerosis$0
P01 · FY2001 · AI
ANTIGEN PRESENTATION IN HUMAN AUTOIMMUNE DISEASES$655,979
P01 · FY2000 · AI
SPECIFICITY AND DEGENERACY OF AUTOREACTIVE T CELL RECEPT$302,079
R01 · FY2000 · NS
TCR recognition of MHC class II peptide compexes in multiple sclerosis$214,842
P01 · FY2000 · AI
MOLECULAR MECHANISMS OF MHC LINKED SUSCEPTIBILITY$197,668
R01 · FY2000 · AI